Welcome in the research database

AIDS and HIV

The HIV-AIDS Unit of the Geneva University Hospitals is the primary care provider for approximately 800 patients . The unit has contributed to better treatments by conducting clinical research projects. Fifteen years ago, we showned that pentamine inhalations prevented Pneumocystis carinii pneumonia. We discovered a new type of bacterium, called Mycobacterium genavense, causing disseminated infections in patients with advanced AIDS. Starting in 1995, the HIV-AIDS Unit has concentrated on antiretroviral therapies and its principal interest currently lies in intermittent treatment. After a pilot study between 1999 and 2001, the concept of intermittent therapy is being explored with large comparative studies of which the first will end at the end of 2005.

Group's publications

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
AIDS
2009 vol. 23(8) pp. 929-939
CALMY A AND AL.

The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection
AIDS
2009 vol. 23(11) pp. 1415-1423
YERLY S AND AL.

Is it smart to continue to study treatment interruptions?
AIDS : A YEAR IN REVIEW
2009 vol. 23(7) pp. 757-759
HIRSCHEL B, FLANIGAN T

A new era of antiretroviral drug toxicity.
ANTIVIRAL THERAPY
2009 vol. 14(2) pp. 165-179
CALMY A, HIRSCHEL B, COOPER DA, CARR A

Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
ANTIVIRAL THERAPY
2009 vol. 14(7) pp. 931-938
CALMY A AND AL.

Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.
ANTIVIRAL THERAPY
2009 vol. 14(3) pp. 349-357
CONEN A. AND AL.

Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.
ANTIVIRAL THERAPY
2009 vol. 14(6) pp. 771-779
YOUNG J AND AL.

Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
CLINICAL INFECTIOUS DISEASES
2009 vol. 48(7) pp. 979-987
VON WYL V. AND AL.

Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.
HEPATOLOGY
2009 vol. 50(4) pp. 1017-1029
RAUCH A. AND AL.

Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.
HIV CLINICAL TRIALS
2009 vol. 10(4) pp. 207-214
ELZI L AND AL.

Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
JOURNAL OF CLINICAL EPIDEMIOLOGY
2009 vol. 62(6) pp. 632-641
YOUNG J. AND AL.

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
JOURNAL OF INFECTIOUS DISEASES
2009 vol. 200(11) pp. 1746-1754
CALMY A, FUX CA, NORRIS R, VALLIER N, DELHUMEAU C, SAMARAS K, HESSE K, HIRSCHEL B, COOPER DA, CARR A

Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.
PLOS ONE
2009 vol. 4(12) pp. 8275-8275
BALLIF M AND AL.

Antiretroviral treatment during pregnancy.
AIDS
2008 vol. 22(17) pp. 2323-2330
KEISER O AND AL.

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
AIDS
2008 vol. 22(16) pp. 2187-2198
COZZI-LEPRI A AND AL

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
AIDS
2008 vol. 22(16) pp. 2143-2153
MONFORTE A AND AL

Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.
AIDS
2008 vol. 22(16) pp. 2135-2141
CLIFFORD GM, RICKENBACH M, POLESEL J, DAL MASO L, STEFFEN I, LEDERGERBER B, RAUCH A, PROBST-HENSCH NM, BOUCHARDY C, LEVI F, FRANCESCHI S, SWISS HIV COHORT

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
AIDS
2008 vol. 22(1) pp. 152-154
NÜESCH R, ANANWORANICH J, SRASUEBKUL P, CHETCHOTISAKD P, PRASITHSIRIKUL W, KLINBUAYAM W, MAHANONTHARIT A, JUPIMAI T, RUXRUNGTHAM K, HIRSCHEL B

Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
AIDS
2008 vol. 22(15) pp. 2013-2017
BROSSARD P AND AL.

Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
AIDS
2008 vol. 22(9) pp. 1019-1028
EL AMARI EB, TOUTOUS-TRELLU LAURENCE, GAYET-AGERON A, BAUMANN M, CATHOMAS G, STEFFEN I, ERB P, MUELLER NJ, FURRER H, CAVASSINI M, VERNAZZA P, HIRSCH HH, BERNASCONI E, HIRSCHEL B

The Monark trial: where now for boosted protease inhibitor monotherapy?
AIDS
2008 vol. 22(6) pp. 777-779
HILL A, HIRSCHEL B, KATLAMA C

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
AIDS
2008 vol. ;22(17) pp. 2279-2289
FOX Z AND AL.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
ANNALS OF INTERNAL MEDICINE
2008 vol. 149(5) pp. 289-299
EL-SADR WM AND AL.

HIV transmission hunting--the chase for low risk events.
ANTIVIRAL THERAPY
2008 vol. 13(5) pp. 641-642
VERNAZZA PL, HIRSCHEL B

Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
ANTIVIRAL THERAPY
2008 vol. 13(3) pp. 375-380
ANANWORANICH J AND AL.

Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
ANTIVIRAL THERAPY
2008 vol. 13(1) pp. 77-85
GLASS TR AND AL.

Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
ANTIVIRAL THERAPY
2008 vol. 13(8) pp. 1077-1082
FUX CA AND AL.

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
BRITISH JOURNAL OF CANCER
2008 vol. 99(5) pp. 800-804
FRANCESCHI S, MASO LD, RICKENBACH M, POLESEL J, HIRSCHEL B, CAVASSINI M, BORDONI A, ELZI L, ESS S, JUNDT G, MUELLER N, CLIFFORD GM

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
CLINICAL INFECTIOUS DISEASES
2008 vol. 47(8) pp. 1093-1101
KHANNA N AND AL.

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
CLINICAL INFECTIOUS DISEASES
2008 vol. 46(7) pp. 1101-1110
SABIN CA AND AL.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
CLINICAL INFECTIOUS DISEASES
2008 vol. 46(8) pp. 1299-1309
VON WYL V AND AL.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
CLINICAL INFECTIOUS DISEASES
2008 vol. 46(8) pp. 1299-1309
VON WYL V AND AL.

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.
CLINICAL INFECTIOUS DISEASES
2008 vol. 46(12) pp. 1921-1925
RAUCH A AND AL.

Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study.
HIV MEDICINE
2008 vol. 9(6) pp. 427-432
WUNDER DM, FUX CA, BERSINGER NA, MUELLER NJ, HIRSCHEL B, CAVASSINI M, ELZI L, SCHMID P, BERNASCONI E, MUELLER B, FURRER H

Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study.
HIV MEDICINE
2008 vol. 9(6) pp. 397-405
WOLBERS M, BUCHER HC, FURRER H, RICKENBACH M, CAVASSINI M, WEBER R, SCHMID P, BERNASCONI E, HIRSCHEL B, BATTEGAY M

Loss to follow-up in an international, multicentre observational study.
HIV MEDICINE
2008 vol. 9(5) pp. 261-269
MOCROFT A AND AL.

Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting.
INTERNATIONAL JOURNAL OF STD & AIDS
2008 vol. 19(8) pp. 529-532
MANGCLAVIRAJ S, KERR SJ, CHAITHONGWONGWATTHANA S, ANANWORANICH J, HIRSCHEL B, EMERY S, COOPER DA, CHOTNOPPARATPATTARA P, RUXRUNGTHAM K, PHANUPHAK P

Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999)
2008 vol. 48(3) pp. 324-333
BANNISTER WP AND AL.

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
JOURNAL OF INFECTIOUS DISEASES
2008 vol. 197(12) pp. 1685-1694
VO TT, LEDERGERBER B, KEISER O, HIRSCHEL B, FURRER H, BATTEGAY M, CAVASSINI M, BERNASCONI E, VERNAZZA P, WEBER R

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
JOURNAL OF INFECTIOUS DISEASES
2008 vol. 197(8) pp. 1145-1155
LUNDGREN JD AND AL.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
JOURNAL OF INFECTIOUS DISEASES
2008 vol. 197(8) pp. 1133-1144
EMERY S AND AL.

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir.
JOURNAL OF INFECTIOUS DISEASES
2008 vol. 198(6) pp. 864-867
COLOMBO S AND AL.

HIV transmission under highly active antiretroviral therapy.
LANCET
2008 vol. 372(9652) pp. 1806-1807
VERNAZZA P, HIRSCHEL B, BERNASCONI E, FLEPP M

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
LANCET
2008 vol. 371(9622) pp. 1417-1426
SABIN CA AND AL.

Initial treatment for HIV infection--an embarrassment of riches.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 358(20) pp. 2170-2172
HIRSCHEL B, CALMY A

Maraviroc for previously treated patients with R5 HIV-1 infection.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 359(14) pp. 1429-1441
GULICK RM AND AL.

Raltegravir with optimized background therapy for resistant HIV-1 infection.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 359(4) pp. 339-354
STEIGBIGEL RT AND AL.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 359(14) pp. 1442-1455
FÄTKENHEUER G AND AL.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
NEW ENGLAND JOURNAL OF MEDICINE
2008 vol. 359(4) pp. 355-365
COOPER DA AND AL.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
2008 vol. 27(5) pp. 431-437
RUDIN C AND AL.

Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.
PLOS MEDICINE
2008 vol. 5(7) pp. 148-148
KEISER O AND AL.

HIV rebounds from latently infected cells, rather than from continuing low-level replication.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
2008 vol. 105(43) pp. 16725-16730
JOOS B AND AL.

A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort.
STATISTICS IN MEDICINE
2008 vol. 27(23) pp. 4835-4853
TAFFÉ P, MAY M, SWISS HIV COHORT STUDY

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
2008 vol. 61(6) pp. 1340-1343
ANANWORANICH J, NUESCH R, CÔTÉ HC, KERR SJ, HILL A, JUPIMAI T, LAOPRAYNAK N, SAENAWAT S, RUXRUNGTHAM K, HIRSCHEL B

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
AIDS
2007 vol. 21 pp. 2201-2207
WOLBERS, M, OPRAVIL, M, VON WYL, V, HIRSCHEL, B, FURRER, H, CAVASSINI, M, VERNAZZA, P, BERNASCONI, E, BATTEGAY, M, YERLY, S, GUENTHARD, H, BUCHER, HC

The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial
AIDS
2007 vol. 21 pp. 1309-1315
VERNAZZA, P, DANEEL, S, SCHIFFER, V, DECOSTERD, L, FIERZ, W, KLIMKAIT, T, HOFFMANN, M, HIRSCHEL, B

Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey
AIDS
2007 vol. 21 pp. 2223-2229
YERLY, S, VON WYL, V, LEDERGERBER, B, BONI, J, SCHUPBACH, J, BURGISSER, P, KLIMKAIT, T, RICKENBACH, M, KAISER, L, GUNTHARD, HF, PERRIN, L

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
ANTIVIRAL THERAPY
2007 vol. 12 pp. 931-939
SIMCOCK, M, BLASKO, M, KARRER, U, BERTISCH, B, PLESS, M, BLUMER, L, VORA, S, ROBINSON, JO, BERNASCONI, E, TERZIROLI, B, MOIRANDAT-RYTZ, S, FURRER, H, HIRSCHEL, B, VERNAZZA, P, SENDI, P, RICKENBACH, M, BUCHER, HC, BATTEGAY, M, KOLLER, MT

Sudden infant death syndrome in infants born to HIV-infected and opiate-using mothers
ARCHIVES OF DISEASE IN CHILDHOOD
2007 vol. 92(11) pp. 1005-1008
KAHLERT CHRISTIAN, RUDIN CHRISTOPH, KIND CHRISTIAN, SWISS HIV COHORT (SHCS), MOCHIV

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination Antiretroviral treatment - A comparison of different regimen types
ARCHIVES OF INTERNAL MEDICINE
2007 vol. 167 pp. 1782-1790
VON WYL, V, YERLY, S, BONI, J, BURGISSER, P, KLIMKAIT, T, BATTEGAY, M, FURRER, H, TELENTI, A, HIRSCHEL, B, VERNAZZA, PL, BERNASCONI, E, RICKENBACH, M, PERRIN, L, LEDERGERBER, B, GUNTHARD, HF

Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission
CLINICAL INFECTIOUS DISEASES
2007 vol. 44 pp. 94-102
ELZI LUIGIA ET AL.

Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression
JOURNAL OF VIROLOGY
2007 vol. 81 pp. 6742-6751
FRATER, AJ, BROWN, H, OXENIUS, A, GUENTHARD, HF, HIRSCHEL, B, ROBINSON, N, LESLIE, AJ, PAYNE, R, CRAWFORD, H, PRENDERGAST, A, BRANDER, C, KIEPIELA, P, WALKER, BD, GOULDER, PJR, MCLEAN, A, PHILLIPS, RE

Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes
JOURNAL OF VIROLOGY
2007 vol. 81(18) pp. 9693-9706
KAISER PHILIPP, JOOS BEDA, NIEDERÖST BARBARA, WEBER RAINER, GÜNTHARD HULDRYCH F., FISCHER MAREK, SWISS HIV COHORT STUDY

HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts
PLOS MEDICINE
2007 vol. 4(3) pp. 96-
GASSER OLIVIER ET AL.

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir
ANTIVIRAL THERAPY
2006 vol. 11 pp. 631-635
ANANWORANICH J, HIRSCHEL B, SIRIVICHAYAKUL S, UBOLYAM S, JUPIMAI T, PRASITHSIRIKUL W, CHETCHOTISAKD P, KIERTIBURANAKUL S, MUNSAKUL W, RAKSAKULKARN P, TANSUPHASAWADIKUL S, SCHUTZ M, SNOWDEN W, RUXRUNGTHAM K

Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
ANTIVIRAL THERAPY
2006 vol. 11(2) pp. 131-142
ZINKERNAGEL AS ET AL.

Molecular biology of squamous cell carcinoma of the anus
BRITISH JOURNAL OF SURGERY
2006 vol. 93 pp. 531-538
GERVAZ P, HIRSCHEL B, MOREL P

HIV viral load monitoring in resource-limited regions: optional or necessary?
CLINICAL INFECTIOUS DISEASES
2006 vol. 44(1) pp. 128-134
CALMY ALEXANDRA, FORD NATHAN, HIRSCHEL BERNARD, REYNOLDS STEVEN J., LYNEN LUT, GOEMAERE ERIC, GARCIA DE LA VEGA FELIPE, PERRIN LUC, RODRIGUEZ WILLIAM

Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission
CLINICAL INFECTIOUS DISEASES
2006 vol. 44(1) pp. 94-102
ELZI LUIGIA ET AL.

Increased incidence of sexually transmitted infections in Geneva, Switzerland
DERMATOLOGY--
2006 vol. 212 pp. 41-46
ABRAHAM S, TOUTOUS-TRELLU L, PECHERE M, HUGONNET S, LIASSINE N, YERLY S, ROHNER P, NINET B, HIRSCHEL B, PIGUET V

Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
HIV MEDICINE
2006 vol. 7 pp. 404-410
GLASS TR, UNGSEDHAPAND C, WOLBERS M, WEBER R, VERNAZZA PL, RICKENBACH M, FURRER H, BERNASCONI E, CAVASSINI M, HIRSCHEL B, BATTEGAY M, BUCHER HC

Correlates of self-reported nonadherence to antiretroviral therapy in HIV-Infected patients - The Swiss HIV cohort study
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
2006 vol. 41 pp. 385-392
GLASS TR, DE GEEST S, WEBER R, VERNAZZA PL, RICKENBACH M, FURRER H, BERNASCONI E, CAVASSINI M, HIRSCHEL B, BATTEGAY M, BUCHER HC

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial
LANCET
2006 vol. 368 pp. 459-465
ANANWORANICH J ET AL.

Immunological recovery and antiretroviral therapy in HIV-1 infection
LANCET INFECTIOUS DISEASES
2006 vol. 6 pp. 280-287
BATTEGAY M, NUESCH R, HIRSCHEL B, KAUFMANN GR

HIV and solid organ transplantation: The Swiss experience
SWISS MEDICAL WEEKLY
2006 vol. 136 pp. 194-196
MULLER NJ, HIRSCHEL B, FURRER H, KAISER L, CAVASSINI M, FELLAY J, CHAVE JP, WUTHRICH RP, WEBER M, MULLHAUPT B, CANDINAS D, REICHEN F, GIOSTRA E, MENTHA G, HALKIC N, HIRSCH HH, WEBER R

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
AIDS
2002 vol. 16 pp. 1967-1969
GREUB G, COZZI-LEPRI A, LEDERGERBER B, STASZEWSKI S, PERRIN L, MILLER V, FRANCIOLI P, FURRER H, BATTEGAY M, VERNAZZA P, BERNASCONI E, HIRSCHEL B, GUNTHARD HF, PHILLIPS A, TELENTI A

Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients : the Swiss HIV Cohort Study
HIV MEDICINE
2002 vol. 3 pp. 247-253
HIRSCHEL B, SWISS HIV COHORT STUDY

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs : the Swiss HIV Cohort Study
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999)
2002 vol. 31 pp. 50-55
BERNASCONI E, BOUBAKER K, JUNGHANS C, FLEPP M, FURRER HJ, HAENSEL A, HIRSCHEL B, BOGGIAN K, CHAVE JP, OPRAVIL M, WEBER R, RICKENBACH M, TELENTI A, SWISS HIV COHORT STUDY

Research's domains




DATABASE-RESEARCH	GROUP OF CLINICAL PATIENT RESEARCH

Bernard HIRSCHEL	Head of group CV	Research subject	Members of the group


	Links about the group Prof. B. HIRSCHEL HUG/ Dpt Médecine interne Serv. maladies infectieuses Rue Gabrielle-Perret-Gentil 4 1211 Genève 14 Suisse Bernard.Hirschel@hcuge.ch Tel.: 022/372.98.10 Fax: 022/372.98.30 Comments Pages updated the 17.11.2015		Reseach's subject \| Group's publications \| Research's domains AIDS and HIV The HIV-AIDS Unit of the Geneva University Hospitals is the primary care provider for approximately 800 patients . The unit has contributed to better treatments by conducting clinical research projects. Fifteen years ago, we showned that pentamine inhalations prevented Pneumocystis carinii pneumonia. We discovered a new type of bacterium, called Mycobacterium genavense, causing disseminated infections in patients with advanced AIDS. Starting in 1995, the HIV-AIDS Unit has concentrated on antiretroviral therapies and its principal interest currently lies in intermittent treatment. After a pilot study between 1999 and 2001, the concept of intermittent therapy is being explored with large comparative studies of which the first will end at the end of 2005. Group's publications HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009 vol. 23(8) pp. 929-939 CALMY A AND AL. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection AIDS 2009 vol. 23(11) pp. 1415-1423 YERLY S AND AL. Is it smart to continue to study treatment interruptions? AIDS : A YEAR IN REVIEW 2009 vol. 23(7) pp. 757-759 HIRSCHEL B, FLANIGAN T A new era of antiretroviral drug toxicity. ANTIVIRAL THERAPY 2009 vol. 14(2) pp. 165-179 CALMY A, HIRSCHEL B, COOPER DA, CARR A Safety and efficacy of once-daily nevirapine dosing: a multicohort study. ANTIVIRAL THERAPY 2009 vol. 14(7) pp. 931-938 CALMY A AND AL. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. ANTIVIRAL THERAPY 2009 vol. 14(3) pp. 349-357 CONEN A. AND AL. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. ANTIVIRAL THERAPY 2009 vol. 14(6) pp. 771-779 YOUNG J AND AL. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. CLINICAL INFECTIOUS DISEASES 2009 vol. 48(7) pp. 979-987 VON WYL V. AND AL. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. HEPATOLOGY 2009 vol. 50(4) pp. 1017-1029 RAUCH A. AND AL. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV CLINICAL TRIALS 2009 vol. 10(4) pp. 207-214 ELZI L AND AL. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. JOURNAL OF CLINICAL EPIDEMIOLOGY 2009 vol. 62(6) pp. 632-641 YOUNG J. AND AL. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. JOURNAL OF INFECTIOUS DISEASES 2009 vol. 200(11) pp. 1746-1754 CALMY A, FUX CA, NORRIS R, VALLIER N, DELHUMEAU C, SAMARAS K, HESSE K, HIRSCHEL B, COOPER DA, CARR A Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLOS ONE 2009 vol. 4(12) pp. 8275-8275 BALLIF M AND AL. Antiretroviral treatment during pregnancy. AIDS 2008 vol. 22(17) pp. 2323-2330 KEISER O AND AL. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 2008 vol. 22(16) pp. 2187-2198 COZZI-LEPRI A AND AL HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 vol. 22(16) pp. 2143-2153 MONFORTE A AND AL Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008 vol. 22(16) pp. 2135-2141 CLIFFORD GM, RICKENBACH M, POLESEL J, DAL MASO L, STEFFEN I, LEDERGERBER B, RAUCH A, PROBST-HENSCH NM, BOUCHARDY C, LEVI F, FRANCESCHI S, SWISS HIV COHORT Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 2008 vol. 22(1) pp. 152-154 NÜESCH R, ANANWORANICH J, SRASUEBKUL P, CHETCHOTISAKD P, PRASITHSIRIKUL W, KLINBUAYAM W, MAHANONTHARIT A, JUPIMAI T, RUXRUNGTHAM K, HIRSCHEL B Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study. AIDS 2008 vol. 22(15) pp. 2013-2017 BROSSARD P AND AL. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008 vol. 22(9) pp. 1019-1028 EL AMARI EB, TOUTOUS-TRELLU LAURENCE, GAYET-AGERON A, BAUMANN M, CATHOMAS G, STEFFEN I, ERB P, MUELLER NJ, FURRER H, CAVASSINI M, VERNAZZA P, HIRSCH HH, BERNASCONI E, HIRSCHEL B The Monark trial: where now for boosted protease inhibitor monotherapy? AIDS 2008 vol. 22(6) pp. 777-779 HILL A, HIRSCHEL B, KATLAMA C Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008 vol. ;22(17) pp. 2279-2289 FOX Z AND AL. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. ANNALS OF INTERNAL MEDICINE 2008 vol. 149(5) pp. 289-299 EL-SADR WM AND AL. HIV transmission hunting--the chase for low risk events. ANTIVIRAL THERAPY 2008 vol. 13(5) pp. 641-642 VERNAZZA PL, HIRSCHEL B Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. ANTIVIRAL THERAPY 2008 vol. 13(3) pp. 375-380 ANANWORANICH J AND AL. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. ANTIVIRAL THERAPY 2008 vol. 13(1) pp. 77-85 GLASS TR AND AL. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. ANTIVIRAL THERAPY 2008 vol. 13(8) pp. 1077-1082 FUX CA AND AL. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. BRITISH JOURNAL OF CANCER 2008 vol. 99(5) pp. 800-804 FRANCESCHI S, MASO LD, RICKENBACH M, POLESEL J, HIRSCHEL B, CAVASSINI M, BORDONI A, ELZI L, ESS S, JUNDT G, MUELLER N, CLIFFORD GM CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. CLINICAL INFECTIOUS DISEASES 2008 vol. 47(8) pp. 1093-1101 KHANNA N AND AL. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. CLINICAL INFECTIOUS DISEASES 2008 vol. 46(7) pp. 1101-1110 SABIN CA AND AL. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. CLINICAL INFECTIOUS DISEASES 2008 vol. 46(8) pp. 1299-1309 VON WYL V AND AL. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. CLINICAL INFECTIOUS DISEASES 2008 vol. 46(8) pp. 1299-1309 VON WYL V AND AL. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. CLINICAL INFECTIOUS DISEASES 2008 vol. 46(12) pp. 1921-1925 RAUCH A AND AL. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV MEDICINE 2008 vol. 9(6) pp. 427-432 WUNDER DM, FUX CA, BERSINGER NA, MUELLER NJ, HIRSCHEL B, CAVASSINI M, ELZI L, SCHMID P, BERNASCONI E, MUELLER B, FURRER H Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV MEDICINE 2008 vol. 9(6) pp. 397-405 WOLBERS M, BUCHER HC, FURRER H, RICKENBACH M, CAVASSINI M, WEBER R, SCHMID P, BERNASCONI E, HIRSCHEL B, BATTEGAY M Loss to follow-up in an international, multicentre observational study. HIV MEDICINE 2008 vol. 9(5) pp. 261-269 MOCROFT A AND AL. Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. INTERNATIONAL JOURNAL OF STD & AIDS 2008 vol. 19(8) pp. 529-532 MANGCLAVIRAJ S, KERR SJ, CHAITHONGWONGWATTHANA S, ANANWORANICH J, HIRSCHEL B, EMERY S, COOPER DA, CHOTNOPPARATPATTARA P, RUXRUNGTHAM K, PHANUPHAK P Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999) 2008 vol. 48(3) pp. 324-333 BANNISTER WP AND AL. Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. JOURNAL OF INFECTIOUS DISEASES 2008 vol. 197(12) pp. 1685-1694 VO TT, LEDERGERBER B, KEISER O, HIRSCHEL B, FURRER H, BATTEGAY M, CAVASSINI M, BERNASCONI E, VERNAZZA P, WEBER R Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. JOURNAL OF INFECTIOUS DISEASES 2008 vol. 197(8) pp. 1145-1155 LUNDGREN JD AND AL. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. JOURNAL OF INFECTIOUS DISEASES 2008 vol. 197(8) pp. 1133-1144 EMERY S AND AL. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. JOURNAL OF INFECTIOUS DISEASES 2008 vol. 198(6) pp. 864-867 COLOMBO S AND AL. HIV transmission under highly active antiretroviral therapy. LANCET 2008 vol. 372(9652) pp. 1806-1807 VERNAZZA P, HIRSCHEL B, BERNASCONI E, FLEPP M Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. LANCET 2008 vol. 371(9622) pp. 1417-1426 SABIN CA AND AL. Initial treatment for HIV infection--an embarrassment of riches. NEW ENGLAND JOURNAL OF MEDICINE 2008 vol. 358(20) pp. 2170-2172 HIRSCHEL B, CALMY A Maraviroc for previously treated patients with R5 HIV-1 infection. NEW ENGLAND JOURNAL OF MEDICINE 2008 vol. 359(14) pp. 1429-1441 GULICK RM AND AL. Raltegravir with optimized background therapy for resistant HIV-1 infection. NEW ENGLAND JOURNAL OF MEDICINE 2008 vol. 359(4) pp. 339-354 STEIGBIGEL RT AND AL. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. NEW ENGLAND JOURNAL OF MEDICINE 2008 vol. 359(14) pp. 1442-1455 FÄTKENHEUER G AND AL. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. NEW ENGLAND JOURNAL OF MEDICINE 2008 vol. 359(4) pp. 355-365 COOPER DA AND AL. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. PEDIATRIC INFECTIOUS DISEASE JOURNAL 2008 vol. 27(5) pp. 431-437 RUDIN C AND AL. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLOS MEDICINE 2008 vol. 5(7) pp. 148-148 KEISER O AND AL. HIV rebounds from latently infected cells, rather than from continuing low-level replication. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008 vol. 105(43) pp. 16725-16730 JOOS B AND AL. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. STATISTICS IN MEDICINE 2008 vol. 27(23) pp. 4835-4853 TAFFÉ P, MAY M, SWISS HIV COHORT STUDY Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2008 vol. 61(6) pp. 1340-1343 ANANWORANICH J, NUESCH R, CÔTÉ HC, KERR SJ, HILL A, JUPIMAI T, LAOPRAYNAK N, SAENAWAT S, RUXRUNGTHAM K, HIRSCHEL B Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study AIDS 2007 vol. 21 pp. 2201-2207 WOLBERS, M, OPRAVIL, M, VON WYL, V, HIRSCHEL, B, FURRER, H, CAVASSINI, M, VERNAZZA, P, BERNASCONI, E, BATTEGAY, M, YERLY, S, GUENTHARD, H, BUCHER, HC The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial AIDS 2007 vol. 21 pp. 1309-1315 VERNAZZA, P, DANEEL, S, SCHIFFER, V, DECOSTERD, L, FIERZ, W, KLIMKAIT, T, HOFFMANN, M, HIRSCHEL, B Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey AIDS 2007 vol. 21 pp. 2223-2229 YERLY, S, VON WYL, V, LEDERGERBER, B, BONI, J, SCHUPBACH, J, BURGISSER, P, KLIMKAIT, T, RICKENBACH, M, KAISER, L, GUNTHARD, HF, PERRIN, L Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study ANTIVIRAL THERAPY 2007 vol. 12 pp. 931-939 SIMCOCK, M, BLASKO, M, KARRER, U, BERTISCH, B, PLESS, M, BLUMER, L, VORA, S, ROBINSON, JO, BERNASCONI, E, TERZIROLI, B, MOIRANDAT-RYTZ, S, FURRER, H, HIRSCHEL, B, VERNAZZA, P, SENDI, P, RICKENBACH, M, BUCHER, HC, BATTEGAY, M, KOLLER, MT Sudden infant death syndrome in infants born to HIV-infected and opiate-using mothers ARCHIVES OF DISEASE IN CHILDHOOD 2007 vol. 92(11) pp. 1005-1008 KAHLERT CHRISTIAN, RUDIN CHRISTOPH, KIND CHRISTIAN, SWISS HIV COHORT (SHCS), MOCHIV Emergence of HIV-1 drug resistance in previously untreated patients initiating combination Antiretroviral treatment - A comparison of different regimen types ARCHIVES OF INTERNAL MEDICINE 2007 vol. 167 pp. 1782-1790 VON WYL, V, YERLY, S, BONI, J, BURGISSER, P, KLIMKAIT, T, BATTEGAY, M, FURRER, H, TELENTI, A, HIRSCHEL, B, VERNAZZA, PL, BERNASCONI, E, RICKENBACH, M, PERRIN, L, LEDERGERBER, B, GUNTHARD, HF Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission CLINICAL INFECTIOUS DISEASES 2007 vol. 44 pp. 94-102 ELZI LUIGIA ET AL. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression JOURNAL OF VIROLOGY 2007 vol. 81 pp. 6742-6751 FRATER, AJ, BROWN, H, OXENIUS, A, GUENTHARD, HF, HIRSCHEL, B, ROBINSON, N, LESLIE, AJ, PAYNE, R, CRAWFORD, H, PRENDERGAST, A, BRANDER, C, KIEPIELA, P, WALKER, BD, GOULDER, PJR, MCLEAN, A, PHILLIPS, RE Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes JOURNAL OF VIROLOGY 2007 vol. 81(18) pp. 9693-9706 KAISER PHILIPP, JOOS BEDA, NIEDERÖST BARBARA, WEBER RAINER, GÜNTHARD HULDRYCH F., FISCHER MAREK, SWISS HIV COHORT STUDY HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts PLOS MEDICINE 2007 vol. 4(3) pp. 96- GASSER OLIVIER ET AL. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir ANTIVIRAL THERAPY 2006 vol. 11 pp. 631-635 ANANWORANICH J, HIRSCHEL B, SIRIVICHAYAKUL S, UBOLYAM S, JUPIMAI T, PRASITHSIRIKUL W, CHETCHOTISAKD P, KIERTIBURANAKUL S, MUNSAKUL W, RAKSAKULKARN P, TANSUPHASAWADIKUL S, SCHUTZ M, SNOWDEN W, RUXRUNGTHAM K Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study ANTIVIRAL THERAPY 2006 vol. 11(2) pp. 131-142 ZINKERNAGEL AS ET AL. Molecular biology of squamous cell carcinoma of the anus BRITISH JOURNAL OF SURGERY 2006 vol. 93 pp. 531-538 GERVAZ P, HIRSCHEL B, MOREL P HIV viral load monitoring in resource-limited regions: optional or necessary? CLINICAL INFECTIOUS DISEASES 2006 vol. 44(1) pp. 128-134 CALMY ALEXANDRA, FORD NATHAN, HIRSCHEL BERNARD, REYNOLDS STEVEN J., LYNEN LUT, GOEMAERE ERIC, GARCIA DE LA VEGA FELIPE, PERRIN LUC, RODRIGUEZ WILLIAM Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission CLINICAL INFECTIOUS DISEASES 2006 vol. 44(1) pp. 94-102 ELZI LUIGIA ET AL. Increased incidence of sexually transmitted infections in Geneva, Switzerland DERMATOLOGY-- 2006 vol. 212 pp. 41-46 ABRAHAM S, TOUTOUS-TRELLU L, PECHERE M, HUGONNET S, LIASSINE N, YERLY S, ROHNER P, NINET B, HIRSCHEL B, PIGUET V Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study HIV MEDICINE 2006 vol. 7 pp. 404-410 GLASS TR, UNGSEDHAPAND C, WOLBERS M, WEBER R, VERNAZZA PL, RICKENBACH M, FURRER H, BERNASCONI E, CAVASSINI M, HIRSCHEL B, BATTEGAY M, BUCHER HC Correlates of self-reported nonadherence to antiretroviral therapy in HIV-Infected patients - The Swiss HIV cohort study JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 2006 vol. 41 pp. 385-392 GLASS TR, DE GEEST S, WEBER R, VERNAZZA PL, RICKENBACH M, FURRER H, BERNASCONI E, CAVASSINI M, HIRSCHEL B, BATTEGAY M, BUCHER HC CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial LANCET 2006 vol. 368 pp. 459-465 ANANWORANICH J ET AL. Immunological recovery and antiretroviral therapy in HIV-1 infection LANCET INFECTIOUS DISEASES 2006 vol. 6 pp. 280-287 BATTEGAY M, NUESCH R, HIRSCHEL B, KAUFMANN GR HIV and solid organ transplantation: The Swiss experience SWISS MEDICAL WEEKLY 2006 vol. 136 pp. 194-196 MULLER NJ, HIRSCHEL B, FURRER H, KAISER L, CAVASSINI M, FELLAY J, CHAVE JP, WUTHRICH RP, WEBER M, MULLHAUPT B, CANDINAS D, REICHEN F, GIOSTRA E, MENTHA G, HALKIC N, HIRSCH HH, WEBER R Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy AIDS 2002 vol. 16 pp. 1967-1969 GREUB G, COZZI-LEPRI A, LEDERGERBER B, STASZEWSKI S, PERRIN L, MILLER V, FRANCIOLI P, FURRER H, BATTEGAY M, VERNAZZA P, BERNASCONI E, HIRSCHEL B, GUNTHARD HF, PHILLIPS A, TELENTI A Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients : the Swiss HIV Cohort Study HIV MEDICINE 2002 vol. 3 pp. 247-253 HIRSCHEL B, SWISS HIV COHORT STUDY Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs : the Swiss HIV Cohort Study JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (1999) 2002 vol. 31 pp. 50-55 BERNASCONI E, BOUBAKER K, JUNGHANS C, FLEPP M, FURRER HJ, HAENSEL A, HIRSCHEL B, BOGGIAN K, CHAVE JP, OPRAVIL M, WEBER R, RICKENBACH M, TELENTI A, SWISS HIV COHORT STUDY Research's domains